G
Giuseppe Altavilla
Researcher at University of Messina
Publications - 122
Citations - 9080
Giuseppe Altavilla is an academic researcher from University of Messina. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 27, co-authored 122 publications receiving 8087 citations. Previous affiliations of Giuseppe Altavilla include University of Turin.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Giorgio V. Scagliotti,F. De Marinis,M. Rinaldi,Lucio Crinò,C. Gridelli,S. Ricci,E. Matano,Corrado Boni,M. Marangolo,G. Failla,Giuseppe Altavilla,Vincenzo Adamo,Anna Ceribelli,M. Clerici,F. Di Costanzo,L. Frontini,Maurizio Tonato +16 more
TL;DR: Efficacy end points were not significantly different between experimental and reference arms, although toxicities showed differences, which suggest that chemotherapy in NSCLC has reached a therapeutic plateau.
Journal ArticleDOI
Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions.
Rossella Marullo,Erica Werner,Natalya Degtyareva,Bryn S. Moore,Giuseppe Altavilla,Suresh S. Ramalingam,Paul W. Doetsch +6 more
TL;DR: Exposure to cisplatin induces a mitochondrial-dependent ROS response that significantly enhances the cytotoxic effect caused by nDNA damage and may lead to the design of novel therapeutic strategies to improve anticancer drug efficacy.
Journal ArticleDOI
Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56brightCD16− cells and display an impaired capability to kill tumor cells
Paolo Carrega,Barbara Morandi,Roberta Costa,Guido Frumento,Giuseppe Forte,Giuseppe Altavilla,Giovanni Battista Ratto,Maria Cristina Mingari,Lorenzo Moretta,Guido Ferlazzo +9 more
TL;DR: Despite natural killer cells being originally identified and named because of their ability to kill tumor cells in vitro, only limited information is available on NK cells infiltrating malignant tumors, especially in humans.
Journal ArticleDOI
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
L. Crinò,Giorgio V. Scagliotti,M. Marangolo,F Figoli,M. Clerici,F. De Marinis,F. Salvati,Giorgio Cruciani,L. Dogliotti,F. Pucci,Adriano Paccagnella,Vincenzo Adamo,Giuseppe Altavilla,P. Incoronato,M Trippetti,Anna Maria Mosconi,Antonella Santucci,S Sorbolini,C Oliva,Maurizio Tonato +19 more
TL;DR: The combination of gemcitabine and cisplatin induced a high response rate in both stage IIIB and IV NSCLC, with modest side effects, and deserves further careful evaluation in a phase III prospective randomized trial.